Anna Radominska-Pandya
Concepts (418)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glucuronosyltransferase | 55 | 2019 | 157 | 9.980 |
Why?
| Microsomes, Liver | 27 | 2020 | 214 | 2.200 |
Why?
| Indoles | 15 | 2020 | 289 | 1.980 |
Why?
| Naphthalenes | 13 | 2021 | 126 | 1.970 |
Why?
| Receptor, Cannabinoid, CB1 | 9 | 2021 | 128 | 1.880 |
Why?
| Glucuronides | 17 | 2012 | 57 | 1.790 |
Why?
| Recombinant Proteins | 28 | 2020 | 570 | 1.450 |
Why?
| Tretinoin | 7 | 2008 | 56 | 1.440 |
Why?
| Cannabinoids | 10 | 2021 | 108 | 1.350 |
Why?
| Liver | 16 | 2020 | 1226 | 1.240 |
Why?
| Kinetics | 26 | 2020 | 692 | 1.220 |
Why?
| Isoenzymes | 15 | 2011 | 177 | 1.140 |
Why?
| Photoaffinity Labels | 11 | 2006 | 15 | 1.100 |
Why?
| Gene Expression Regulation, Enzymologic | 8 | 2007 | 206 | 1.090 |
Why?
| Adamantane | 3 | 2020 | 33 | 1.080 |
Why?
| Tamoxifen | 3 | 2016 | 61 | 1.080 |
Why?
| Indazoles | 3 | 2020 | 55 | 1.080 |
Why?
| Phenylalanine | 4 | 2011 | 125 | 0.950 |
Why?
| Estrogens | 5 | 2011 | 244 | 0.930 |
Why?
| Stilbenes | 3 | 2014 | 65 | 0.920 |
Why?
| Uridine Diphosphate Glucuronic Acid | 5 | 2019 | 10 | 0.870 |
Why?
| Warfarin | 4 | 2011 | 87 | 0.840 |
Why?
| Intestines | 9 | 2020 | 204 | 0.830 |
Why?
| Receptor, Cannabinoid, CB2 | 4 | 2021 | 60 | 0.810 |
Why?
| Intestinal Mucosa | 7 | 2011 | 259 | 0.780 |
Why?
| Humans | 88 | 2021 | 54391 | 0.710 |
Why?
| Binding Sites | 15 | 2010 | 440 | 0.690 |
Why?
| Microsomes | 9 | 2020 | 45 | 0.690 |
Why?
| Antineoplastic Agents | 6 | 2021 | 1300 | 0.630 |
Why?
| Substrate Specificity | 14 | 2014 | 209 | 0.620 |
Why?
| Breast Neoplasms | 6 | 2016 | 1249 | 0.600 |
Why?
| Receptors, Retinoic Acid | 3 | 2002 | 27 | 0.600 |
Why?
| Molecular Sequence Data | 14 | 2011 | 980 | 0.590 |
Why?
| RNA, Messenger | 11 | 2008 | 1203 | 0.580 |
Why?
| Metabolic Detoxication, Phase II | 3 | 2011 | 12 | 0.580 |
Why?
| Chromatography, High Pressure Liquid | 12 | 2020 | 377 | 0.570 |
Why?
| Lithocholic Acid | 4 | 2005 | 13 | 0.540 |
Why?
| Hepatocytes | 3 | 2009 | 214 | 0.530 |
Why?
| Oxidation-Reduction | 8 | 2020 | 383 | 0.510 |
Why?
| Aspartic Acid | 2 | 2007 | 48 | 0.510 |
Why?
| Animals | 35 | 2020 | 14409 | 0.510 |
Why?
| Selective Estrogen Receptor Modulators | 2 | 2016 | 25 | 0.510 |
Why?
| Nanomedicine | 1 | 2014 | 22 | 0.490 |
Why?
| Disease | 1 | 2014 | 28 | 0.480 |
Why?
| Drug Inverse Agonism | 1 | 2013 | 18 | 0.480 |
Why?
| Mass Spectrometry | 8 | 2014 | 313 | 0.470 |
Why?
| Receptors, Cytoplasmic and Nuclear | 5 | 2005 | 85 | 0.460 |
Why?
| Amino Acid Sequence | 12 | 2011 | 767 | 0.460 |
Why?
| Linoleic Acids | 3 | 2001 | 10 | 0.450 |
Why?
| Models, Molecular | 8 | 2011 | 423 | 0.450 |
Why?
| Mutagenesis, Site-Directed | 9 | 2011 | 117 | 0.450 |
Why?
| Digestive System | 2 | 2003 | 19 | 0.450 |
Why?
| Pancreatic Neoplasms | 2 | 2015 | 234 | 0.440 |
Why?
| Chromatography, Liquid | 7 | 2013 | 243 | 0.430 |
Why?
| Cytochrome P-450 CYP3A | 4 | 2020 | 82 | 0.420 |
Why?
| Promoter Regions, Genetic | 2 | 2014 | 520 | 0.420 |
Why?
| Hemiterpenes | 1 | 2011 | 10 | 0.420 |
Why?
| Receptors, Steroid | 4 | 2004 | 21 | 0.410 |
Why?
| Receptors, Cannabinoid | 1 | 2011 | 20 | 0.410 |
Why?
| Tandem Mass Spectrometry | 7 | 2013 | 248 | 0.400 |
Why?
| Transcription Factors | 3 | 2005 | 622 | 0.400 |
Why?
| Binding, Competitive | 7 | 2021 | 113 | 0.390 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2014 | 552 | 0.390 |
Why?
| Ligands | 6 | 2021 | 229 | 0.390 |
Why?
| Uridine Diphosphate | 2 | 2010 | 4 | 0.390 |
Why?
| Glucuronates | 5 | 2007 | 21 | 0.380 |
Why?
| Protein Binding | 7 | 2020 | 736 | 0.380 |
Why?
| Arylsulfotransferase | 2 | 2000 | 20 | 0.370 |
Why?
| Estradiol | 3 | 2007 | 219 | 0.370 |
Why?
| Cell Membrane | 3 | 2013 | 279 | 0.360 |
Why?
| Pharmaceutical Preparations | 1 | 2010 | 86 | 0.340 |
Why?
| Metabolic Networks and Pathways | 2 | 2020 | 104 | 0.340 |
Why?
| Kidney | 2 | 2014 | 822 | 0.340 |
Why?
| Catalysis | 7 | 2012 | 98 | 0.330 |
Why?
| Hydroxylation | 7 | 2014 | 61 | 0.330 |
Why?
| Acridines | 3 | 2012 | 5 | 0.320 |
Why?
| Polymorphism, Genetic | 2 | 2020 | 193 | 0.320 |
Why?
| Retinoids | 1 | 2008 | 9 | 0.320 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2008 | 674 | 0.320 |
Why?
| Cytochrome P-450 Enzyme System | 6 | 2012 | 192 | 0.310 |
Why?
| Breast | 1 | 2008 | 92 | 0.300 |
Why?
| Triazoles | 3 | 2012 | 119 | 0.300 |
Why?
| Blotting, Western | 6 | 2008 | 684 | 0.290 |
Why?
| Caco-2 Cells | 5 | 2008 | 50 | 0.290 |
Why?
| Cells, Cultured | 7 | 2008 | 1737 | 0.290 |
Why?
| Base Sequence | 6 | 2008 | 719 | 0.280 |
Why?
| Cell Line, Tumor | 6 | 2021 | 1551 | 0.270 |
Why?
| Gastric Mucosa | 2 | 2003 | 59 | 0.270 |
Why?
| Bile Acids and Salts | 4 | 2004 | 76 | 0.270 |
Why?
| Deoxycholic Acid | 2 | 2003 | 17 | 0.270 |
Why?
| Cloning, Molecular | 6 | 2007 | 198 | 0.270 |
Why?
| Endoplasmic Reticulum | 3 | 2005 | 123 | 0.260 |
Why?
| CHO Cells | 3 | 2016 | 123 | 0.250 |
Why?
| Prostaglandins B | 1 | 2004 | 1 | 0.250 |
Why?
| Coumarins | 3 | 2011 | 7 | 0.250 |
Why?
| Gastrointestinal Tract | 4 | 2007 | 136 | 0.250 |
Why?
| Dinoprostone | 1 | 2004 | 55 | 0.250 |
Why?
| Aminoacridines | 3 | 2012 | 5 | 0.250 |
Why?
| Structure-Activity Relationship | 5 | 2010 | 423 | 0.240 |
Why?
| Sulfotransferases | 2 | 2006 | 43 | 0.240 |
Why?
| Gene Expression | 3 | 2005 | 664 | 0.240 |
Why?
| Protein Kinase C | 2 | 2002 | 65 | 0.240 |
Why?
| DNA Primers | 5 | 2008 | 225 | 0.240 |
Why?
| Designer Drugs | 2 | 2013 | 28 | 0.230 |
Why?
| Catechols | 1 | 2003 | 7 | 0.230 |
Why?
| Fatty Acids | 1 | 2004 | 175 | 0.230 |
Why?
| Cell Line | 7 | 2004 | 1152 | 0.230 |
Why?
| Cannabinoid Receptor Antagonists | 2 | 2020 | 18 | 0.220 |
Why?
| Mice | 9 | 2020 | 6428 | 0.220 |
Why?
| Carcinoma, Hepatocellular | 1 | 2005 | 203 | 0.220 |
Why?
| Phytanic Acid | 1 | 2002 | 1 | 0.220 |
Why?
| Male | 20 | 2020 | 27347 | 0.220 |
Why?
| Female | 18 | 2020 | 28471 | 0.220 |
Why?
| Amino Acids | 3 | 2006 | 369 | 0.210 |
Why?
| Nuclear Envelope | 1 | 2002 | 4 | 0.210 |
Why?
| Nanotubes, Carbon | 2 | 2014 | 70 | 0.210 |
Why?
| Docosahexaenoic Acids | 1 | 2002 | 29 | 0.210 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 462 | 0.210 |
Why?
| Benzoxazines | 1 | 2021 | 18 | 0.210 |
Why?
| Sarcoma, Ewing | 1 | 2021 | 22 | 0.200 |
Why?
| Linolenic Acids | 1 | 2001 | 2 | 0.200 |
Why?
| Glutathione Transferase | 1 | 2002 | 178 | 0.200 |
Why?
| Morpholines | 1 | 2021 | 64 | 0.200 |
Why?
| Liver Neoplasms | 1 | 2005 | 352 | 0.200 |
Why?
| Protein Structure, Tertiary | 4 | 2011 | 289 | 0.200 |
Why?
| Xenobiotics | 3 | 2010 | 27 | 0.200 |
Why?
| Sequence Homology, Amino Acid | 5 | 2011 | 180 | 0.190 |
Why?
| Cricetinae | 4 | 2016 | 209 | 0.190 |
Why?
| Cytochrome P-450 CYP2D6 | 1 | 2020 | 25 | 0.190 |
Why?
| Biotransformation | 5 | 2012 | 100 | 0.180 |
Why?
| Rats | 13 | 2012 | 3419 | 0.180 |
Why?
| Molecular Structure | 5 | 2013 | 319 | 0.180 |
Why?
| Glutamic Acid | 1 | 2000 | 111 | 0.180 |
Why?
| Aryl Hydrocarbon Hydroxylases | 5 | 2013 | 70 | 0.180 |
Why?
| Sequence Alignment | 4 | 2007 | 146 | 0.180 |
Why?
| Middle Aged | 11 | 2007 | 13082 | 0.180 |
Why?
| Androgens | 1 | 1999 | 68 | 0.170 |
Why?
| Convulsants | 1 | 2018 | 7 | 0.170 |
Why?
| Transfection | 4 | 2015 | 399 | 0.170 |
Why?
| Periodic Acid | 1 | 1998 | 4 | 0.170 |
Why?
| Valine | 1 | 2018 | 54 | 0.160 |
Why?
| Histidine | 1 | 1998 | 17 | 0.160 |
Why?
| Intracellular Membranes | 1 | 1998 | 26 | 0.160 |
Why?
| Adult | 9 | 2007 | 14207 | 0.160 |
Why?
| Tritium | 3 | 2003 | 53 | 0.160 |
Why?
| Cricetulus | 2 | 2016 | 102 | 0.150 |
Why?
| Protein Isoforms | 2 | 2011 | 124 | 0.150 |
Why?
| Sex Factors | 1 | 2020 | 766 | 0.150 |
Why?
| Glucuronic Acid | 2 | 2011 | 9 | 0.150 |
Why?
| Methylcholanthrene | 3 | 2007 | 10 | 0.150 |
Why?
| Carrier Proteins | 2 | 2004 | 360 | 0.150 |
Why?
| Genistein | 2 | 2007 | 46 | 0.150 |
Why?
| Adolescent | 8 | 2006 | 6900 | 0.150 |
Why?
| Seizures | 1 | 2018 | 209 | 0.140 |
Why?
| Rifampin | 2 | 2007 | 57 | 0.140 |
Why?
| Polymerase Chain Reaction | 2 | 2008 | 531 | 0.140 |
Why?
| Stereoisomerism | 3 | 2011 | 106 | 0.140 |
Why?
| Enzyme Induction | 4 | 2004 | 80 | 0.130 |
Why?
| Anticoagulants | 2 | 2009 | 270 | 0.130 |
Why?
| Solid Phase Extraction | 2 | 2013 | 12 | 0.130 |
Why?
| Dopamine | 2 | 2008 | 190 | 0.130 |
Why?
| Down-Regulation | 2 | 2008 | 388 | 0.130 |
Why?
| Xanthones | 1 | 2014 | 3 | 0.130 |
Why?
| MCF-7 Cells | 1 | 2015 | 79 | 0.130 |
Why?
| Metabolomics | 2 | 2013 | 149 | 0.130 |
Why?
| Toremifene | 1 | 2014 | 3 | 0.130 |
Why?
| Mice, Inbred C57BL | 1 | 2020 | 2001 | 0.120 |
Why?
| Graphite | 1 | 2014 | 31 | 0.120 |
Why?
| Sequence Analysis, Protein | 2 | 2006 | 21 | 0.120 |
Why?
| Pharmacogenetics | 1 | 2014 | 55 | 0.120 |
Why?
| Drug Carriers | 1 | 2014 | 82 | 0.120 |
Why?
| Signal Transduction | 2 | 2002 | 1752 | 0.120 |
Why?
| Nanotechnology | 1 | 2014 | 39 | 0.120 |
Why?
| Substance-Related Disorders | 2 | 2018 | 671 | 0.120 |
Why?
| Organ Specificity | 3 | 2003 | 126 | 0.120 |
Why?
| Wounds, Stab | 1 | 2013 | 8 | 0.120 |
Why?
| Models, Chemical | 2 | 2006 | 65 | 0.120 |
Why?
| Benzoflavones | 1 | 2013 | 3 | 0.110 |
Why?
| Sulfaphenazole | 1 | 2013 | 4 | 0.110 |
Why?
| Neck Injuries | 1 | 2013 | 26 | 0.110 |
Why?
| Self-Injurious Behavior | 1 | 2013 | 29 | 0.110 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2014 | 255 | 0.110 |
Why?
| Aged | 5 | 2007 | 10060 | 0.110 |
Why?
| Enzyme Activation | 4 | 2006 | 328 | 0.110 |
Why?
| Biological Availability | 2 | 2011 | 131 | 0.110 |
Why?
| Cytosol | 2 | 2003 | 101 | 0.110 |
Why?
| Genotype | 1 | 2014 | 600 | 0.110 |
Why?
| Phosphoadenosine Phosphosulfate | 2 | 2003 | 3 | 0.110 |
Why?
| Phenols | 2 | 2007 | 122 | 0.110 |
Why?
| Crystallography, X-Ray | 2 | 2010 | 178 | 0.110 |
Why?
| Metabolic Clearance Rate | 2 | 2010 | 75 | 0.110 |
Why?
| Prenylation | 1 | 2011 | 3 | 0.100 |
Why?
| Tissue Banks | 1 | 2011 | 8 | 0.100 |
Why?
| Anti-Infective Agents | 1 | 2013 | 111 | 0.100 |
Why?
| Enzyme Inhibitors | 4 | 2019 | 446 | 0.100 |
Why?
| Spectrophotometry, Ultraviolet | 1 | 2011 | 33 | 0.100 |
Why?
| Oxygenases | 1 | 2011 | 10 | 0.100 |
Why?
| Ethylenediamines | 1 | 2011 | 5 | 0.100 |
Why?
| Genes, p53 | 1 | 2011 | 60 | 0.100 |
Why?
| Hydrogen-Ion Concentration | 5 | 2000 | 194 | 0.100 |
Why?
| Substance Abuse Detection | 1 | 2011 | 92 | 0.100 |
Why?
| Colon | 2 | 2003 | 111 | 0.090 |
Why?
| Genetic Therapy | 1 | 2011 | 121 | 0.090 |
Why?
| Cell Proliferation | 1 | 2015 | 1097 | 0.090 |
Why?
| Behavior, Animal | 1 | 2012 | 202 | 0.090 |
Why?
| Hydrolysis | 2 | 2000 | 68 | 0.090 |
Why?
| Peptide Fragments | 2 | 2002 | 242 | 0.090 |
Why?
| Mammals | 1 | 2010 | 59 | 0.090 |
Why?
| Cell Survival | 2 | 2012 | 657 | 0.090 |
Why?
| Uterine Cervical Neoplasms | 1 | 2012 | 276 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 3 | 2018 | 1476 | 0.090 |
Why?
| DNA, Complementary | 3 | 2005 | 145 | 0.090 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 2 | 2011 | 67 | 0.080 |
Why?
| Baculoviridae | 2 | 2005 | 5 | 0.080 |
Why?
| Benzoates | 1 | 2008 | 22 | 0.080 |
Why?
| Amino Acid Motifs | 1 | 2007 | 57 | 0.080 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 2007 | 59 | 0.080 |
Why?
| Naphthols | 2 | 2006 | 10 | 0.080 |
Why?
| Receptors, Estrogen | 1 | 2007 | 131 | 0.070 |
Why?
| Pyrazoles | 1 | 2007 | 110 | 0.070 |
Why?
| Hymecromone | 1 | 2006 | 1 | 0.070 |
Why?
| Azides | 1 | 2006 | 9 | 0.070 |
Why?
| Salicylates | 1 | 2006 | 10 | 0.070 |
Why?
| Phenol | 1 | 2006 | 10 | 0.070 |
Why?
| Lipid Metabolism | 2 | 2004 | 194 | 0.070 |
Why?
| Nitrophenols | 1 | 2006 | 15 | 0.070 |
Why?
| Cytochrome P-450 CYP2E1 | 1 | 2006 | 105 | 0.070 |
Why?
| Sulfates | 1 | 2006 | 27 | 0.070 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 79 | 0.070 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 142 | 0.070 |
Why?
| Chenodeoxycholic Acid | 1 | 2005 | 8 | 0.070 |
Why?
| Isoflavones | 1 | 2006 | 83 | 0.070 |
Why?
| Up-Regulation | 1 | 2007 | 509 | 0.070 |
Why?
| Oligonucleotide Probes | 1 | 2005 | 21 | 0.070 |
Why?
| Chromatography | 1 | 2005 | 16 | 0.070 |
Why?
| Cannabinoid Receptor Agonists | 2 | 2016 | 50 | 0.060 |
Why?
| Child, Preschool | 2 | 2007 | 4158 | 0.060 |
Why?
| Hydroxyeicosatetraenoic Acids | 1 | 2004 | 20 | 0.060 |
Why?
| Receptors, Virus | 1 | 2004 | 30 | 0.060 |
Why?
| Heme | 2 | 2003 | 24 | 0.060 |
Why?
| GTP-Binding Proteins | 2 | 2016 | 94 | 0.060 |
Why?
| Rats, Sprague-Dawley | 3 | 2012 | 1664 | 0.060 |
Why?
| Ketoprofen | 2 | 2004 | 2 | 0.060 |
Why?
| Computer Simulation | 2 | 2006 | 332 | 0.060 |
Why?
| Plasmids | 1 | 2004 | 180 | 0.060 |
Why?
| Drug Interactions | 1 | 2004 | 206 | 0.060 |
Why?
| Dehydroepiandrosterone | 1 | 2003 | 16 | 0.060 |
Why?
| Child | 3 | 2003 | 7368 | 0.060 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2007 | 868 | 0.060 |
Why?
| Steroids | 1 | 2003 | 55 | 0.060 |
Why?
| Cytochrome P-450 CYP1A2 | 2 | 2013 | 46 | 0.050 |
Why?
| Glycosylation | 1 | 2003 | 112 | 0.050 |
Why?
| Glutathione S-Transferase pi | 1 | 2002 | 20 | 0.050 |
Why?
| Chromatography, Thin Layer | 2 | 2001 | 32 | 0.050 |
Why?
| Brain | 3 | 2020 | 1392 | 0.050 |
Why?
| Retinoid X Receptors | 1 | 2002 | 16 | 0.050 |
Why?
| Inhibitory Concentration 50 | 2 | 2012 | 80 | 0.050 |
Why?
| Receptors, LDL | 1 | 2002 | 70 | 0.050 |
Why?
| Intestine, Small | 1 | 2003 | 123 | 0.050 |
Why?
| Fluorescent Antibody Technique | 1 | 2002 | 141 | 0.050 |
Why?
| Cytotoxins | 1 | 2021 | 17 | 0.050 |
Why?
| Reference Values | 1 | 2002 | 354 | 0.050 |
Why?
| Cholesterol | 1 | 2002 | 155 | 0.050 |
Why?
| Carcinogens | 1 | 2003 | 231 | 0.050 |
Why?
| Autoradiography | 1 | 2001 | 36 | 0.050 |
Why?
| Isoxazoles | 1 | 2000 | 16 | 0.050 |
Why?
| Microscopy, Fluorescence | 1 | 2002 | 198 | 0.050 |
Why?
| Indicators and Reagents | 1 | 2000 | 42 | 0.050 |
Why?
| Estriol | 1 | 2000 | 5 | 0.050 |
Why?
| Cholestasis | 1 | 2001 | 45 | 0.050 |
Why?
| Blotting, Northern | 1 | 2000 | 108 | 0.050 |
Why?
| Glucosyltransferases | 1 | 2000 | 10 | 0.050 |
Why?
| Cattle | 1 | 2000 | 225 | 0.050 |
Why?
| Tryptophan | 1 | 2000 | 102 | 0.050 |
Why?
| Metalloendopeptidases | 1 | 2000 | 84 | 0.050 |
Why?
| Lysine | 1 | 2000 | 102 | 0.050 |
Why?
| Affinity Labels | 1 | 1999 | 9 | 0.040 |
Why?
| Conserved Sequence | 1 | 1999 | 57 | 0.040 |
Why?
| Glutamine | 1 | 2000 | 168 | 0.040 |
Why?
| Catalytic Domain | 1 | 1999 | 61 | 0.040 |
Why?
| RNA | 1 | 2000 | 202 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 124 | 0.040 |
Why?
| Arginine | 1 | 2000 | 182 | 0.040 |
Why?
| Androsterone | 1 | 1998 | 2 | 0.040 |
Why?
| Fluorescent Dyes | 1 | 1999 | 116 | 0.040 |
Why?
| Immunohistochemistry | 1 | 2002 | 1090 | 0.040 |
Why?
| Phosphorus Radioisotopes | 1 | 1998 | 20 | 0.040 |
Why?
| Jejunum | 1 | 1998 | 56 | 0.040 |
Why?
| Tyrosine | 1 | 1999 | 137 | 0.040 |
Why?
| Uridine Diphosphate Sugars | 1 | 1998 | 1 | 0.040 |
Why?
| Diethyl Pyrocarbonate | 1 | 1998 | 2 | 0.040 |
Why?
| Acetophenones | 1 | 1998 | 13 | 0.040 |
Why?
| Isotope Labeling | 1 | 1998 | 58 | 0.040 |
Why?
| Ileum | 1 | 1998 | 103 | 0.040 |
Why?
| Testosterone | 1 | 1998 | 119 | 0.040 |
Why?
| Nitro Compounds | 1 | 1998 | 14 | 0.040 |
Why?
| Imidazoles | 1 | 1999 | 143 | 0.040 |
Why?
| Benzenesulfonates | 1 | 1998 | 12 | 0.040 |
Why?
| Cross-Linking Reagents | 1 | 1998 | 42 | 0.040 |
Why?
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2016 | 13 | 0.040 |
Why?
| Isomerism | 1 | 2016 | 24 | 0.040 |
Why?
| Cyclohexanols | 1 | 2016 | 23 | 0.040 |
Why?
| Cyclic AMP | 1 | 2016 | 106 | 0.040 |
Why?
| L-Lactate Dehydrogenase | 1 | 2014 | 79 | 0.030 |
Why?
| Microscopy, Electron, Transmission | 1 | 2014 | 87 | 0.030 |
Why?
| Models, Biological | 2 | 2012 | 825 | 0.030 |
Why?
| Paper | 1 | 2013 | 16 | 0.030 |
Why?
| Capsules | 1 | 2013 | 34 | 0.030 |
Why?
| Pentanones | 1 | 2013 | 9 | 0.030 |
Why?
| Methylamines | 1 | 2013 | 16 | 0.030 |
Why?
| Powders | 1 | 2013 | 32 | 0.030 |
Why?
| Tablets | 1 | 2013 | 31 | 0.030 |
Why?
| Bilirubin | 2 | 2004 | 49 | 0.030 |
Why?
| Tissue Distribution | 1 | 2013 | 178 | 0.030 |
Why?
| Hallucinogens | 1 | 2013 | 62 | 0.030 |
Why?
| Benzodioxoles | 1 | 2013 | 56 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 225 | 0.030 |
Why?
| Pyrans | 1 | 2012 | 27 | 0.030 |
Why?
| Pyrrolidines | 1 | 2013 | 88 | 0.030 |
Why?
| Drug Partial Agonism | 1 | 2012 | 7 | 0.030 |
Why?
| Drug Antagonism | 1 | 2012 | 10 | 0.030 |
Why?
| HeLa Cells | 1 | 2012 | 291 | 0.030 |
Why?
| Body Temperature | 1 | 2012 | 83 | 0.030 |
Why?
| Alcohols | 1 | 2011 | 8 | 0.030 |
Why?
| Biocatalysis | 1 | 2011 | 20 | 0.030 |
Why?
| Hep G2 Cells | 1 | 2011 | 46 | 0.030 |
Why?
| Deuterium | 1 | 2011 | 41 | 0.030 |
Why?
| Thermogravimetry | 1 | 2011 | 4 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2012 | 199 | 0.030 |
Why?
| Reference Standards | 1 | 2011 | 63 | 0.030 |
Why?
| Microscopy, Atomic Force | 1 | 2011 | 29 | 0.030 |
Why?
| Macrophages | 1 | 2014 | 404 | 0.030 |
Why?
| Microscopy, Electron, Scanning | 1 | 2011 | 52 | 0.030 |
Why?
| Glucuronidase | 1 | 2011 | 48 | 0.020 |
Why?
| Cell Hypoxia | 1 | 2011 | 87 | 0.020 |
Why?
| Green Fluorescent Proteins | 1 | 2011 | 110 | 0.020 |
Why?
| Caspase 3 | 1 | 2011 | 135 | 0.020 |
Why?
| Staining and Labeling | 1 | 2011 | 106 | 0.020 |
Why?
| Methamphetamine | 1 | 2013 | 233 | 0.020 |
Why?
| Central Nervous System Stimulants | 1 | 2013 | 255 | 0.020 |
Why?
| Tissue Donors | 1 | 2011 | 112 | 0.020 |
Why?
| Mitochondria | 1 | 2014 | 490 | 0.020 |
Why?
| Analysis of Variance | 1 | 2011 | 634 | 0.020 |
Why?
| Drug Delivery Systems | 1 | 2011 | 151 | 0.020 |
Why?
| Mice, Knockout | 2 | 2003 | 927 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 922 | 0.020 |
Why?
| Gene Expression Regulation | 2 | 2004 | 1063 | 0.020 |
Why?
| Neurons | 1 | 2012 | 486 | 0.020 |
Why?
| DNA Mutational Analysis | 1 | 2007 | 217 | 0.020 |
Why?
| Glycoside Hydrolases | 1 | 1975 | 27 | 0.020 |
Why?
| Bacillus subtilis | 1 | 1975 | 17 | 0.020 |
Why?
| Ethers | 1 | 1975 | 6 | 0.020 |
Why?
| Digitoxin | 1 | 1975 | 5 | 0.020 |
Why?
| Pentosephosphates | 1 | 1975 | 1 | 0.020 |
Why?
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1975 | 3 | 0.020 |
Why?
| Sodium Salicylate | 1 | 1975 | 3 | 0.020 |
Why?
| Formates | 1 | 1975 | 4 | 0.020 |
Why?
| Mutation | 1 | 2012 | 1504 | 0.020 |
Why?
| Body Fluids | 1 | 1975 | 26 | 0.020 |
Why?
| Etodolac | 1 | 2004 | 1 | 0.020 |
Why?
| Naproxen | 1 | 2004 | 8 | 0.020 |
Why?
| Apoptosis | 1 | 2011 | 1302 | 0.020 |
Why?
| Coxsackie and Adenovirus Receptor-Like Membrane Protein | 1 | 2004 | 2 | 0.020 |
Why?
| Enzymes | 1 | 2004 | 31 | 0.020 |
Why?
| Schizophrenia | 1 | 1976 | 267 | 0.010 |
Why?
| Species Specificity | 1 | 2004 | 206 | 0.010 |
Why?
| Antipsychotic Agents | 1 | 1976 | 241 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 461 | 0.010 |
Why?
| Young Adult | 1 | 2013 | 4318 | 0.010 |
Why?
| Exons | 1 | 2003 | 105 | 0.010 |
Why?
| Oligodeoxyribonucleotides, Antisense | 1 | 2002 | 4 | 0.010 |
Why?
| Protein Kinase C-epsilon | 1 | 2002 | 5 | 0.010 |
Why?
| Diglycerides | 1 | 2002 | 12 | 0.010 |
Why?
| Type C Phospholipases | 1 | 2002 | 15 | 0.010 |
Why?
| Eicosanoids | 1 | 2002 | 19 | 0.010 |
Why?
| Phospholipids | 1 | 2002 | 63 | 0.010 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2002 | 170 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2002 | 477 | 0.010 |
Why?
| Oxidoreductases, N-Demethylating | 1 | 2001 | 19 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2003 | 658 | 0.010 |
Why?
| Spodoptera | 1 | 2000 | 5 | 0.010 |
Why?
| Transcription, Genetic | 1 | 2002 | 418 | 0.010 |
Why?
| Acid Phosphatase | 1 | 2000 | 15 | 0.010 |
Why?
| Carbohydrate Conformation | 1 | 2000 | 8 | 0.010 |
Why?
| Cell Nucleus | 1 | 2001 | 203 | 0.010 |
Why?
| Glycoproteins | 1 | 2000 | 132 | 0.010 |
Why?
| Saccharomyces cerevisiae | 1 | 2000 | 218 | 0.010 |
Why?
| Antibodies | 1 | 1999 | 178 | 0.010 |
Why?
| Time Factors | 2 | 1975 | 3210 | 0.010 |
Why?
| Promazine | 1 | 1976 | 1 | 0.000 |
Why?
| Nitrophenylgalactosides | 1 | 1975 | 1 | 0.000 |
Why?
| Basal Ganglia Diseases | 1 | 1976 | 7 | 0.000 |
Why?
| Chlorpromazine | 1 | 1976 | 15 | 0.000 |
Why?
| Arabinose | 1 | 1975 | 5 | 0.000 |
Why?
| Trifluoperazine | 1 | 1976 | 9 | 0.000 |
Why?
| Mercury | 1 | 1975 | 8 | 0.000 |
Why?
| Glucosides | 1 | 1975 | 16 | 0.000 |
Why?
| Movement Disorders | 1 | 1976 | 19 | 0.000 |
Why?
| Chromatography, Gel | 1 | 1975 | 47 | 0.000 |
Why?
| Ethyl Ethers | 1 | 1975 | 1 | 0.000 |
Why?
| Benzopyrenes | 1 | 1975 | 6 | 0.000 |
Why?
| Phenobarbital | 1 | 1975 | 17 | 0.000 |
Why?
| Digitoxigenin | 1 | 1975 | 6 | 0.000 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 1975 | 22 | 0.000 |
Why?
| Oligosaccharides | 1 | 1975 | 45 | 0.000 |
Why?
| NADP | 1 | 1975 | 27 | 0.000 |
Why?
| Aldehyde Oxidoreductases | 1 | 1975 | 3 | 0.000 |
Why?
| Methanol | 1 | 1975 | 7 | 0.000 |
Why?
| Haplorhini | 1 | 1975 | 22 | 0.000 |
Why?
| Methods | 1 | 1975 | 66 | 0.000 |
Why?
| Methylene Blue | 1 | 1975 | 12 | 0.000 |
Why?
| Pseudomonas | 1 | 1975 | 11 | 0.000 |
Why?
| Erythrocytes | 1 | 1975 | 98 | 0.000 |
Why?
| Carbon Dioxide | 1 | 1975 | 103 | 0.000 |
Why?
| Recurrence | 1 | 1976 | 692 | 0.000 |
Why?
| Chronic Disease | 1 | 1976 | 614 | 0.000 |
Why?
| Clinical Trials as Topic | 1 | 1976 | 491 | 0.000 |
Why?
| Blood Glucose | 1 | 1975 | 489 | 0.000 |
Why?
|
|
Radominska-Pandya's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|